Excitatory amino acids, monoamines, neuropeptide Y and cholecystokinin in cerebrospinal fluid of Parkinson patients

Biogenic Amines

Volumn 12, Issue 4, 1996, Pages 275-284

  Bednar, Ivan ^a   Baig, Shahid ^b   Silberring, Jerzy ^c   Stenfors, Carina ^c   Södersten, Per ^a   Siden, Åke ^a   Qureshi, G Ali ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Aspartate; Cerebrospinal fluid; Cholecystokinin; Dopamine; Glutamate; Noradrenaline neuropeptide Y; Parkinson's disease

Indexed keywords

ASPARTIC ACID; BROMOCRIPTINE; CHOLECYSTOKININ; CHOLECYSTOKININ OCTAPEPTIDE; DOPAMINE; EXCITATORY AMINO ACID; GLUTAMIC ACID; LEVODOPA; MONOAMINE; NEUROPEPTIDE Y; NORADRENALIN; SELEGILINE; SEROTONIN;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; NEUROTRANSMITTER RELEASE; PARKINSON DISEASE;

EID: 0029811361     PISSN: 01688561     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Agid, Y. and Javoy-Agid, F. (1985) Peptides and Parkinson's disease. Trends NeuroSci., 7, 30-35.
2. Bednar, I., Södersten, P. and Qureshi, G.A. (1992) A simple HPLC method in monitoring catecholamines, tryptophan, and the metabolites in CSF or rats: a role of dopamine and noradrenaline in food intake. J. Liq. Chromatogr., 15, 3087-3096.
3. Chan-Palay, V. (1993) Depression and dementia in Parkinson's disease. Catecholamine changes in the locus coeruleus, a basis for therapy. Adv. Neurol., 60, 438-446.
4. 3H]citalopram. Neuroscience, 54, 691-699.
5. Everitt, B.J., Hökfelt, T, Terenius, L., Tatemoto, K., Mutt, V. and Goldstein, M. (1984) Differential co-existence of NPY-immunoreactivity with catecholamines in the central nervous system of the rat. Neurosciince , 11, 443-463.
6. Flood, J.F., Hernandez, E.N. and Morley, J.E. (1987) Modulation of memory processing by neuropeptide Y. Brain Res. 421, 280-290.
7. Fernandez, A., de Ceballos, M.L., Jenner, P. and Marsden, C.D. (1992) Striatal neuropeptide levels in Parkinson's disease patients. Neurosci. Lett., 145, 171-174.
8. Gerfen, C.R. (1992) The neostriatal mosaic: multiple levels of compartmental organization in the basala ganglia. Annu. Rev. Neurosci., 15, 285-320.
9. Gjessing, L.R., Gjesdahl, P., Deitrichson, P. and Presthu, J. (1974) Free amino acids in the cerebrospinal fluid in old age and in Parkinson's disease. Eur. Neurol., 12, 33-37.
10. Goldstein, M. and Lieberman, A. (1992) The role of the regulatory enzymes of catecholamine synthesis in Parkinson's disease. Neurology, 42 (suppl. 4), 8-12.
11. Halawa, I., Baig, S. and Qureshi, G.A. (1991) Application of HPLC in defining the abnormalities in patients with aseptic meningitis. J. Biomed. Chromatogr., 5, 216-222.
12. Haycock, K., Roth, J., Gaynon, J., Finzer, W.F. and Soper, C. (1992) Statview. Abacus Concepts Inc, Berkeley.
13. Herkenham, M. (1987) Mismatches between neurotransmitter and receptor localizations in brain: observations and implications. Neuroscience, 23, 1-38.
14. Hoehn, M.M. and Yahr, M.D. (1967) Parkinsonism: onset, progression, and mortality. Neurology, 17, 427-442.
15. Hökfelt, T., Rehfeld, J.F., Skirboll, L., Ivemark, B., Goldstein, M. and Markey, K. (1980) Evidence for coexistence of dopamine and CCK in mesolimbic neurons. Nature, 285, 476-478.
16. Hökfelt, T., Lundberg, J.M., Lagercrantz, H., Tatemoto, K., Mutt, V., Lindberg, J., Terenius, L., Everitt, B.J., Fuxe, K., Agnati, L. and Goldstein, M. (1983) Occurrence of neuropeptide Y (NPY)-like immunoreactivity in catecholamine neurons in human medulla oblongata. Neurosci. Lett. 36 , 217-222.
17. Hurst, H.J., Lewitt, P.A., Burns, R.S., Foster, N.L. and Lovenberg, W. (1985) CSF dopamine ß-hydroxylase activity in Parkinson's disease. Neurology, 35, 565-568.
18. Lakke, J.P.W.F. and Teelken, A.W. (1976) Amino acid abnormalities in cerebrospinal fluid of patients with parkinsonism and extrapyramidal disorders. Neurology, 26, 489-493.
19. Lang, A.E. and Fahn, S. (1989) Assessment of Parkinson's disease. In: Munsat, T. L. (ed), Quantification of Neurologic Deficit. Butterworths, Boston, pp. 285-309.
20. Le Vitt, P.A., Galloway, M.P., Matson, W., Milbury, P., McDermott, M., Srivastava, D.K. and Oakes, D. (1992) Markers of dopamine metabolism in Parkinson's disease. Neurology 42, 2111-2117.
21. Link, H. and Tibbling, G. (1977) Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the cental nervous system in multiple sclerosis. Scand. J. CLin., lab. Invest. 37, 297-401.
22. Lotstra, F., Verbanck, P.M., Gilles, C., Mendlewicz, J. and Vanderhaeghen, J.-J. (1985) Reduced cholecystokinin levels in cerebrospinal fluid of parkinsonian and schizophrenic patients. Effect of ceruletide in schizophrenia. Ann. N. Y. Acad. Sci. 448, 507-517.
23. Martignoni, E., Blandini, F., Petraglia, F., Pacchetti, C., Bono, G. and Nappi, G. (1992) Cerebrospinal fluid norepinephrine,3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type. J. Neural Transmiss. (P-D Sect.), 4, 191-205.
24. Meyerson, B.A., Linderoth, B., Karlsson, H. and Ungerstedt, U. (1990) Microdialysis in the human brain: extracellular measurements in the thalamus of parkinsonian patients. Life Sci., 46, 301-308.
25. Montague, P.R., Cancayco, C., Winn, M.J., Marchase, R.B. and Friedlander, M.J. (1994) Role of NO production in NMDA receptor-mediated neurotransmitter release in cerebral cortex. Science, 263, 973-977.
26. Nagatsu, T. (1993) Biochemical aspects of Parkinson's disease. Adv. Neurol., 60, 165-174.
27. Olney, J.W. (1990) Excitatory amino acids and neuropsychiatric disorders. Annu. Rev. Pharmacol. Toxicol., 30, 47-71.
28. Olsson, T., Kostulas, V. and Link, H. (1984) Improved detection of oligoclonal IgG in cerebrospinal fluid by isoelectric focusing in agarose, double-antibody peroxidase labeling, and avidin-biotin amplification. Clin. Chem., 30, 1246-1249.
29. Palacios, J.M., Savasta, M. and Mengod, G. (1989) Does cholecystokinin colocalize with dopamine in the human substantia nigra? Brain Res., 488, 369-375.
30. Perry, T.L., Wright, J.M., Berry, K., Hansen, S. and Perry Jr., T.L. (1990) Dominantly inherited apathy, central hypoventilation, and Parkinson's syndrome: clinical, biochemical, and neuropathologic studies of 2 new cases. Neurology, 40, 1882-1887.
31. Qureshi, G.A., Bednar, I., Min, Q., Södersten, P., Silberring, J., Nyberg, F. and Thörnwall, M. (1993) Quantitation and identification of two cholecystokinin peptides, CCK-4 and CCK-8s, in rat brain by HPLC and fast atom bombardment masspectrometry. Biomed. Chromatogr., 7, 251-255.
32. Qureshi, G.A., Baig, S., Bednar, I., Södersten, P., Forsberg, G. and Siden, Å. (1995) Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease. NeuroReport 6, 1642-1644.
33. Sandyk, R. (1992) L-tryptophan in neuropsychiatrie disorders: a review. Int. J. Neurosci., 67, 127-144.
34. Schalling, M., Friberg, K., Bird, E., Goldstein, M., Schiffmann, S.N., Mailleux, P., Vanderhaegen, J.-J. and Hökfelt, T. (1989) Presence of cholecystokinin mRNA in dopamine cells in the ventral mesencephalon of a human with schizophrenia. Acta Physiol. Scand., 137, 467-468.
35. Schiffmann, S.N., Mailleux, P., Przedborski, S., Halleux, P., Lotstra, F. and Vanderhaegen, J.-J. (1989) Cholecystokinin distribution in the human striatum and related subcortical structures. Neurochem. Internat., 14, 167-173.
36. Sörnäs, R. (1967) A new method for the cytological examination of the cerebrospinal fluid. J. Neurol. Neurosurg. Psych., 30, 568-577.
37. Starke, K., Göthert, M. and Kilbinger, H. (1989) Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol. Rev., 69, 864-989.
38. Theodorsson-Norheim, E. Hemsen, A. and Lundberg, M. (1985) Radioimmunoassay for neuropeptide Y (NPY): chromatographic characterization of immunoreactivity in plasma and tissue extracts. Scand.J.Clin.Lab.Invest. 45, 355-365.
39. Tohgi, H., Abe, T., Takahashi, S., Ueno, M. and Nozaki, Y. (1990) Cerebrospinal fluid dopamine, norepinephrine, and epinephrine concentrations in Parkinson's disease correlated with clinical symptoms. Adv. Neurol., 53, 277-282.
40. Tohgi, H., Abe, T., Hachiguchi, K., Takahashi, S., Nozaki, Y. and Kikuchi, T. (1991) A significant reduction of putative transmitter amino acids in the cerebrospinal fluid of patients with Parkinson's disease and spinocerebellar degeneration. Neurosci. Lett., 27, 126, 155-158.
41. Tohgi, H., Abe, T., Takahashi, S., Takahashi, J. and Hamato, H. (1993) Concentrations of serotonin and its related substances in the cerebrospinal fluid of Parkinsonian patients and their relations to the severity of symptoms. Neurosci. Lett., 150, 71-74.
42. van Sande, M., Caers, J. and Lowenthal, A. (1971) Cerebrospinal fluid amino acids in extrapyramidal disorders before and after L-DOPA treatment. Z. Neurol., 199, 24-29.
43. Wahlestedt, C., Ekman, R. and Widerlöv, E. (1989) NPY and the central nervous system: distribution effects and possible relationship to neurological and psychiatric disorders. Prog.Neuropsychompharm.& Biol.Psychiat. 31, 31-54.
44. Wester, P., Bergström, U., Eriksson, A., Gezelius, C., Hardy, J. and Winblad, B. (1990) Ventricular cerebrospinal fluid monoamine transmitter and metabolite concentrations reflect human brain neurochemistry in autopsy cases. J. Neurochem. 54, 1148-1156.
45. Widerlöv, E., Lindström, H., Wahlestedt, C. and Ekman, R. (1988) NPY and PYY as possible cerebrospinal marker for major depression and schizophrenia respectively. J.Psychiatr.Res. 22, 69-79.
46. Zhang, J., Dawson, V.L., Dawson, T.M. and Snyder, S.H. (1994) Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. Science, 263, 687-689.